MiNK Therapeutics, Inc. (INKT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
INKT currently has 4.8M outstanding shares. with significant dilution risk as 13.1M authorized shares could dilute existing holders by 273.9%. The company has significantly diluted shareholders by 55.64% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 4.8M shares outstanding |
4.8M | 13M |
| Mar 31, 2026 |
10-K filing | 5.0M shares outstanding |
5M | 13M |
| Dec 10, 2025 |
S-3/A filing: MiNK Therapeutics, Inc. files an S-3/A to offer common stock, preferred stock, debt securities, warrants, or units up to an aggregate amount of $150,000,000. |
4.6M | 13M |
| Nov 14, 2025 |
10-Q filing | 4.4M shares outstanding |
4.4M | 9.3M |
| Nov 07, 2025 |
S-3 filing: MiNK Therapeutics, Inc. is filing an S-3 to offer common stock, preferred stock, and debt securities for a total aggregate price of $150,000,000. |
4M | 9.3M |
| Aug 14, 2025 |
10-Q filing | 4.5M shares outstanding |
4.5M | 9.3M |
| May 15, 2025 |
10-Q filing | 4.0M shares outstanding |
4M | 9.3M |
| Mar 18, 2025 |
10-K filing | 3.8M shares outstanding |
3.8M | 9.3M |
| Nov 14, 2024 |
10-Q filing | 39.5M shares outstanding |
40M | 9.3M |
| Aug 13, 2024 |
10-Q filing | 37.1M shares outstanding |
37M | 9.3M |
| Aug 13, 2024 |
S-3 filing: This S-3 filing relates to the potential sale of 4,640,000 shares of common stock by a selling stockholder. |
35M | 9.3M |
| May 16, 2024 |
8-K filing: MiNK Therapeutics, Inc. issued and sold 4,640,000 shares of Common Stock at $1.25 per share to an investor, receiving net proceeds of approximately $5.8 million, and the transaction closed on May 14, 2024. ($0.0M proceeds) |
35M | 4.7M |
| May 14, 2024 |
10-Q filing | 34.6M shares outstanding |
35M | 4.7M |
| Mar 21, 2024 |
10-K filing | 34.4M shares outstanding |
34M | 4.7M |
| Nov 14, 2023 |
10-Q filing | 34.5M shares outstanding |
34M | 4.7M |
| Aug 10, 2023 |
10-Q filing | 34.4M shares outstanding |
34M | 4.7M |
| May 11, 2023 |
10-Q filing | 34.0M shares outstanding |
34M | 4.7M |
| Mar 24, 2023 |
10-K filing | 33.7M shares outstanding |
34M | 4.7M |
| Nov 03, 2022 |
S-3 filing: MiNK Therapeutics, Inc. files an S-3 registration statement to offer common stock, preferred stock, warrants, debt securities, and units for an aggregate initial offering price not to exceed $50,000,000. |
34M | 4.7M |
| Nov 03, 2022 |
10-Q filing | 33.8M shares outstanding |
34M | 4.7M |
| Aug 15, 2022 |
10-Q filing | 33.6M shares outstanding |
34M | 4.7M |
| May 13, 2022 |
10-Q filing | 33.6M shares outstanding |
34M | 4.7M |
| Mar 18, 2022 |
10-K filing | 33.6M shares outstanding |
34M | 4.7M |
| Nov 29, 2021 |
10-Q filing | 33.5M shares outstanding |
34M | 4.7M |
| Oct 12, 2021 |
S-1/A filing: MiNK Therapeutics, Inc. is offering 4,000,000 shares of common stock in an initial public offering. The initial public offering price is expected to be between $12.00 and $14.00 per share. |
N/A | 4.7M |
| Sep 14, 2021 |
S-1 filing: MiNK Therapeutics, Inc. is offering shares of common stock in an initial public offering. The initial public offering price is expected to be between a range. Agenus Inc. will continue to own a majority of the voting power following the completion of this offering. |
N/A | 0 |